Glioblastoma (GBM) remains a significant cause of cancerrelated mortality in pediatric and adult patients with limited treatment options. Immunotherapy represents a promising new therapeutic approach in many solid and hematologic malignancies, including GBM, although only a subset of patients responds clinically. Thus, current efforts are focused on identifying patients most likely to benefit from immune-based therapies. The cancer immunogenomics approach identifies candidate neoantigens from genomics information and represents a potentially exciting new space in precision neuro-oncology. In this review, we discuss the role of neoantigens in GBM both as predictive biomarkers and as targets of immunotherapy.

Original languageEnglish
Pages (from-to)125-130
Number of pages6
JournalCancer Journal (United States)
Issue number2
StatePublished - 2017


  • Biomarker
  • Glioblastoma
  • Hypermutated
  • Immunogenomics
  • Neoantigen
  • Personalized vaccine


Dive into the research topics of 'Applied cancer immunogenomics leveraging neoantigen discovery in glioblastoma'. Together they form a unique fingerprint.

Cite this